Health-related quality of life results from the phase III CheckMate 067 study.

PubWeight™: 0.75^‹?›

🔗 View Article (PMID 28651159)

Published in Eur J Cancer on June 22, 2017

Authors

Dirk Schadendorf¹, James Larkin², Jedd Wolchok³, F Stephen Hodi⁴, Vanna Chiarion-Sileni⁵, Rene Gonzalez⁶, Piotr Rutkowski⁷, Jean-Jacques Grob⁸, C Lance Cowey⁹, Christopher Lao¹⁰, John Wagstaff¹¹, Margaret K Callahan³, Michael A Postow¹², Michael Smylie¹³, Pier Francesco Ferrucci¹⁴, Reinhard Dummer¹⁵, Andrew Hill¹⁶, Fiona Taylor¹⁷, Javier Sabater¹⁸, Dana Walker¹⁸, Srividya Kotapati¹⁸, Amy Abernethy¹⁹, Georgina V Long²⁰

Author Affiliations

1: Department of Dermatology, University of Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany.
2: Royal Marsden Hospital, London, UK.
3: Memorial Sloan Kettering Cancer Center, New York, NY, USA.
4: Dana-Farber Cancer Institute, Boston, MA, USA.
5: Istituto Oncologico Veneto, Veneto, Italy.
6: University of Colorado, Denver, CO, USA.
7: Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
8: Hospital de la Timone, Marseille, France.
9: Texas Oncology-Baylor Cancer Center, Dallas, TX, USA.
10: University of Michigan, Ann Arbor, MI, USA.
11: The College of Medicine, Swansea University, Swansea, UK.
12: Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA.
13: Cross Cancer Institute, Edmonton, Alberta, Canada.
14: Istituto Europeo di Oncologia, Milan, Italy.
15: University of Zurich, Zurich, Switzerland.
16: Tasman Oncology Research, Brisbane, QLD, Australia.
17: Adelphi Values, Boston, MA, USA.
18: Bristol-Myers Squibb, Princeton, NJ, USA.
19: Duke University Medical Center, Durham, NC, USA.
20: Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia. Electronic address: georgina.long@sydney.edu.au.

Articles by these authors ⇆

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (2014) 8.63

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol (2015) 6.07

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol (2014) 4.60

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol (2015) 4.04

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet (2015) 3.13

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol (2015) 2.80

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. Br J Cancer (2018) 1.38

Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. Lancet Oncol (2016) 1.14

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol (2015) 0.89

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol (2017) 0.80

Expanded access programmes: patient interests versus clinical trial integrity. Lancet Oncol (2014) 0.77

Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered. Eur Urol (2016) 0.76

Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. Eur J Cancer (2016) 0.76

Development of a Symptom-Based Patient-Reported Outcome Instrument for Functional Dyspepsia: A Preliminary Conceptual Model and an Evaluation of the Adequacy of Existing Instruments. Patient (2016) 0.75

Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. Eur J Cancer (2017) 0.75

A step forward for patients with NRAS-mutant melanoma. Lancet Oncol (2017) 0.75

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell (2017) 0.75

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer (2017) 0.75

Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. Oncologist (2017) 0.75

Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat Rev (2017) 0.75

Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho. Clin Cancer Res (2017) 0.75

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol (2017) 0.75

Impact of Nivolumab Versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients With Advanced Squamous Non-Small Cell Lung Cancer: Results From the CheckMate 017 Study. J Thorac Oncol (2017) 0.75

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol (2017) 0.75